Neurapexai achieved something that happened almost nowhere else in Shark Tank India Season 5. The AI-assisted diagnostic platform asked for ₹60 lakh for 5% equity — and got exactly that. No cut, no counter, no restructuring. In a season of 50%, 70% and 75% valuation reductions, this is the outlier worth understanding.
- What is Neurapexai?
- The pitch and the deal: identical
- Why this pitch closed at the ask
- The valuation was already conservative
- The equity offered was meaningful
- Healthcare AI has real defensibility
- Small cheque, low risk
- The trade-off founders should weigh
- What founders should take away
- Frequently Asked Questions
- Did Neurapexai get a deal on Shark Tank India Season 5?
- What valuation did Neurapexai get?
- What does Neurapexai do?
- Which Season 5 pitches closed at their exact asking terms?
- The bottom line
What is Neurapexai?
Neurapexai operates an AI-assisted diagnostic platform — software that supports clinicians in interpreting medical data and reaching diagnostic conclusions.
The problem it addresses is one of the most consequential in Indian healthcare. Specialist doctors are heavily concentrated in metros while the majority of patients are not. Radiologists and pathologists in particular are in short supply relative to the volume of scans and samples generated. Software that helps a smaller number of specialists handle more cases accurately, or that helps a general practitioner catch what they might otherwise miss, addresses a genuine structural shortage rather than a convenience.
The pitch and the deal: identical
Neurapexai asked for ₹60 lakh for 5% equity — a ₹12 crore valuation.
The deal closed at ₹60 lakh for 5% equity. The same ₹12 crore valuation.
| Ask | Deal | |
|---|---|---|
| Capital | ₹60 lakh | ₹60 lakh |
| Equity | 5% | 5% |
| Valuation | ₹12 crore | ₹12 crore |
| Royalty / debt | — | None |
Compare that against the rest of the season and the anomaly is obvious. Croffle lost 50% of its valuation. Capture A Trip lost 70%. Corel Lifecare lost 75%. Nootie lost 70% and took a royalty on top. Neurapexai lost nothing.
Why this pitch closed at the ask
The valuation was already conservative
₹12 crore is a genuinely modest number for a healthtech platform with defensible technology. When the ask sits at or below where an investor would independently price the business, there is nothing to negotiate. The founders left money on the table in valuation terms — and bought a frictionless close in exchange.
The equity offered was meaningful
5% is a stake worth an investor’s attention. Season 5 repeatedly punished founders offering 0.5% to 1.5%, because those stakes are too small to justify active involvement. Neurapexai’s structure invited engagement rather than resisting it.
Healthcare AI has real defensibility
Clinical AI requires validated datasets, regulatory pathways and the trust of medical professionals. None of those are quickly replicated. Once a diagnostic tool is embedded in a hospital’s workflow, switching is disruptive and rare — the opposite of the consumer brands elsewhere in the season where the customer can leave after one purchase.
Small cheque, low risk
At ₹60 lakh, this was among the smallest investments of the season. The downside is contained and the upside in healthcare AI is substantial. That asymmetry makes a fast yes easy.
The trade-off founders should weigh
There is a genuine debate inside this outcome. Neurapexai got clean terms and instant conviction — but it also gave up 5% for ₹60 lakh, while GOAT Life gave up 8% for ₹2 crore and SaveSage gave up 9% for ₹4 crore.
Put differently: Neurapexai raised the least capital per point of dilution of any successful pitch in this series. For a company that needs to fund clinical validation, regulatory work and hospital sales cycles, ₹60 lakh does not go far. A founder in this position should ask whether an under-ask that closes instantly is really a win, or whether it signals a plan that was scoped too small.
What founders should take away
- If you want the ask accepted, ask at a number an investor would arrive at independently. That is exactly what Neurapexai did.
- Offer equity that justifies involvement. 5% earns attention; 1% invites an argument.
- But ask for enough. A clean close at a small cheque can leave you back in the market within a year.
Frequently Asked Questions
Did Neurapexai get a deal on Shark Tank India Season 5?
Yes. Neurapexai closed ₹60 lakh for 5% equity — precisely what it asked for.
What valuation did Neurapexai get?
₹12 crore, unchanged from the ask.
What does Neurapexai do?
It runs an AI-assisted diagnostic platform supporting clinical decision-making in healthcare.
Which Season 5 pitches closed at their exact asking terms?
Neurapexai is the clearest example in this series — most deals involved a valuation cut, a larger cheque, advisory equity or a royalty.
The bottom line
Neurapexai is the one pitch in this series where the Sharks simply said yes. That happened because the founders priced the business where an investor would price it and offered a stake worth having. It is the cleanest close of Season 5 — and a reminder that the fastest route to a deal is often to stop negotiating before you start.
